Michael Ashton - Hikma Pharmaceuticals Non-Executive Independent Director
HKMPF Stock | USD 22.33 0.00 0.00% |
Director
Mr. Michael Richard Dwyer Ashton is no longer as NonExecutive Independent Director of Hikma Pharmaceuticals Plc, effective May 2017. Michael has over 30 years experience in the pharmaceutical industry, holding senior executive positions with Pfizer and Merck. Michael was Chief Executive of SkyePharma PLC from November 1998 to March 2006 and prior to that was Chairman, President and Chief Executive of Faulding. He has held a number of nonexecutive and advisory positions across the pharmaceutical industry. Michael has a Bachelor of Pharmacy degree from Sydney University, and an MBA degree from Rutgers University, New Jersey. since 2005.
Age | 69 |
Tenure | 19 years |
Professional Marks | MBA |
Phone | 44 20 7399 2760 |
Web | https://www.hikma.com |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Robert Falls | Green Thumb Industries | 62 | |
Ryan Roebuck | Cronos Group | 31 | |
Anthony Georgiadis | Green Thumb Industries | 45 | |
Kevin Crosthwaite | Cronos Group | 42 | |
Bruce Gates | Cronos Group | 56 | |
Bronwen Evans | Cronos Group | 48 | |
Michael Krestell | Cronos Group | N/A | |
Glen Senk | Green Thumb Industries | 55 | |
Alex Yemenidjian | Green Thumb Industries | 61 | |
Norm Yurik | Green Thumb Industries | N/A | |
Wendy Berger | Green Thumb Industries | N/A | |
Westley Moore | Green Thumb Industries | 40 | |
William Gruver | Green Thumb Industries | 67 | |
Murray Garnick | Cronos Group | 58 | |
Jason Adler | Cronos Group | 46 | |
James Rudyk | Cronos Group | 51 | |
Alan Friedman | Cronos Group | 45 |
Management Performance
Return On Equity | 0.15 | |||
Return On Asset | 0.077 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients | ||
Bassam Kanaan, Chief Strategy & Corporate Development Officer | ||
Khalid Nabilsi, Chief Officer | ||
Hussein Arkhagha, General Counsel | ||
Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
Pamela Kirby, Non-Executive Independent Director | ||
John Castellani, Non-Executive Independent Director | ||
Brian Hoffman, President and Chief Executive of - Generics Division | ||
Ali AlHusry, Non-Executive Director | ||
Jochen Gann, Non-Executive Director | ||
Engineer Darwazah, Ex CEO | ||
Peter Speirs, Company Secretary | ||
Patrick Butler, Non-Executive Independent Director | ||
Brian Hoffmann, Pres Generics | ||
Said Darwazah, Chairman and CEO | ||
Michael Raya, President and CEO, USA | ||
Samuel Park, Global US | ||
Ronald Goode, Non-Executive Independent Director | ||
Bryan Hotston, CIO | ||
Sigurdur Olafsson, CEO | ||
Breffni Byrne, Non-Executive Independent Director | ||
Nina Henderson, Non-Executive Independent Director | ||
Cynthia Schwalm, Independent Non-Executive Director | ||
Ragheb AlShakhshir, Corporate Vice President - Research & Development | ||
Michael Ashton, Non-Executive Independent Director | ||
Majda Labadi, Corporate Vice President - Human Resources | ||
Ibrahim Jalal, Sr. Corporate VP of Technical Affairs | ||
Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
Robert Pickering, Senior Non-Executive Independent Director | ||
Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | ||
CPA CFA, Exec MA |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.15 | |||
Return On Asset | 0.077 | |||
Profit Margin | 0.14 % | |||
Operating Margin | 0.22 % | |||
Current Valuation | 5.26 B | |||
Shares Outstanding | 220.26 M | |||
Shares Owned By Insiders | 29.67 % | |||
Shares Owned By Institutions | 41.69 % | |||
Price To Earning | 7.89 X | |||
Price To Book | 1.84 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hikma Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hikma Pharmaceuticals' short interest history, or implied volatility extrapolated from Hikma Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |